1 National Forum on Biomedical Imaging in Oncology CMS UPDATE Steve Phurrough MD, MPA Director,...
-
Upload
benjamin-harrington -
Category
Documents
-
view
216 -
download
0
description
Transcript of 1 National Forum on Biomedical Imaging in Oncology CMS UPDATE Steve Phurrough MD, MPA Director,...
1
National Forum on Biomedical Imaging in Oncology
CMS UPDATE
Steve Phurrough MD, MPADirector, Coverage and Analysis Group
2
Recent Activities
1. PET scanning• NCI trials• Coverage with evidence development
3
PET for Alzheimer’s Disease
• Limited coverage as differential in FTD
• Clinical trials
4
PET for Cancer Indications
• Added cervical cancer• All current & future noncoverage based on
lack of evidence will be covered with data collection
5
National Decisions
• National Coverage • National Noncoverage• National Coverage with restrictions
– Specific populations– Specific providers/facilities– Evidence development
6CP1027346-1
Percutaneous Coronary Interventions
7
SCD-HeFT
8
Contributors to Variation• Inconsistent use of good evidence• Lack of high quality evidence from studies
selected and designed to inform clinical decisions– Evidence gaps are systematic and widespread– Existing clinical research enterprise will not correct
the problem• CMS aim is to help establish more robust
research enterprise serving decision makers– pts, clinicians, payers, policymakers– One mechanism is through coverage authority
9
Unanswered Questions
• Novel vs conventional imaging• Comparative effectiveness of drugs• Surgical procedures• Off-label uses of approved drugs• 510(k) devices• Risks and benefits of treatments in
subgroups of pts studied• Patients with multiple co-morbidities
10
Developing EvidenceCore concept
• Links coverage with prospective data collection• Extends concept of medical necessity
– Adequate evidence of benefit– Adequate evidence of potential value and provided in
appropriately designed study• i.e. “promising, important, potentially high value, and
under careful investigation”• Retains EBM as conceptual framework for coverage
and payment
11
Problems with EB coverage
• Viewed as interference with pt/doc decisions• Payers appear to impede innovation in order to
control spending / protect profits• Insensitive to real barriers to doing adequate trials,
and different challenges by technology• When evidence limited, may still be strong
demand for technology• Does not promote promising but unproven high
value technologies
12
Benefits of approach• Addresses economic barriers to good trials,
especially for promising technologies• Payers can promote innovation and access, while
supporting better evidence• One strategy to establish clinical research agenda
oriented to decision makers• Strong public/professional demand can be
channeled to improve evidence• Focus discussion around improving evidence
with key stakeholders – product developers, pt advocates, payers, clinicians
13
Key conceptual issues• How to evolve from ad hoc to systematic policy
approach• Priority setting: criteria, participants, process• Roles and governance: what organizations
oversee and implement various functions of the initiative
• Funding– How much can be accomplished by PCE– What are other sustainable sources and mechanisms
of funding– What is the business case for each potential funder?
14
Implementation Issues
• Methods: When to use registries, practical trials, registries, outcomes studies, etc
• Infrastructure: what exists, what needs to be created, how can this be done most efficiently
• Legal and ethical: private payer contractual issues, HIPAA, human subjects, conflicts of interest
15
Next Steps• Guidance on coverage plus data
– Open door forum 2/14– Initial draft guidance soon
• ICD registry workgroup and CMS-NCI collaboration moving forward
• FDA discussions on Post Approval Studies• IOM/AHRQ/CMS discussions
– Larger stakeholder mtg 3/1– Initial focus on registries to “break trail”– Priorities, governance, funding, implementation